

**Table 2**

| <b>Affected Wall<br/>(LGE +)</b> | <b>T1 mapping in case's<br/>affected<br/>wall<br/>(mean ± SD)</b> | <b>p (a)</b> | <b>T1 mapping in all case's<br/>unaffected<br/>walls (LGE-)<br/>(mean ± SD)</b> | <b>p (b)</b> | <b>T1 mapping of<br/>respective wall in<br/>controls<br/>(mean ± SD)</b> | <b>p (c)</b> |
|----------------------------------|---|--------------|---|--------------|--|--------------|
| <b>Anterior<br/>(n)</b>          | 1017 ± 41<br>(7)*   | 0,3201       | 1037 ± 44<br>(15)**   | 0,0013       | 981 ± 47<br>(18)*  | 0,0859       |
| <b>Posterior<br/>(n)</b>         | 1068 ± 47<br>(21)*  | 0,0011       | 1027 ± 49<br>(71)**   | 0,0084       | 994 ± 38<br>(18)*  | <0,0001      |
| <b>Lateral<br/>(n)</b>           | 1075 ± 61<br>(15)*  | 0,0168       | 1032 ± 56<br>(43)**   | 0,0284       | 999 ± 40<br>(18)*  | 0,0002       |
| <b>Inferior<br/>(n)</b>          | 1079 ± 31<br>(7)*   | 0,0037       | 1018 ± 45<br>(15)**   | 0,5783       | 1010 ± 36<br>(18)*   | 0,0002       |
| <b>Posterior Septum<br/>(n)</b>  | 1059 ± 17<br>(4)*   | 0,6912       | 1074 ± 71<br>(8)**  | 0,0038       | 1001 ± 44<br>(18)*   | 0,0191       |
| <b>Anterior Septum<br/>(n)</b>   | 1005 ± 69<br>(4)*   | 0,1450       | 1074 ± 71<br>(8)**  | 0,0023       | 993 ± 48<br>(18)*  | 0,6776       |
| <b>General Mean<br/>(n)</b>      | 1057 ± 30<br>(58)**   | 0,0001       | 1028 ± 48<br>(74)**   | <0,0001      | 996 ± 10<br>(108)**  | <0,0001      |

a: analysis between T1 mapping in cases by affected wall and T1 mapping in all unaffected walls of the same patients; b: analysis between T1 mapping in all case's unaffected walls and T1 mapping of respective wall in controls; c: analysis between T1 mapping in cases by affected wall and and T1 mapping of respective wall in controls. LGE +: presence of late gadolinium enhancement; LGE -: absence of late gadolinium enhancement; SD: standard deviation; n\*: number of patients; n\*\* number of walls assessed.